This was the stock's third consecutive day of losses.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

On Friday, Abbott Laboratories (ABT) stock saw a decline, ending the day at $118.93 which represents a decrease of $-0.02 or -0.02% from the prior close of $118.95. The stock opened at $118.71 and ...

Piper Sandler analyst Adam Maeder maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...

Valued at a market cap of $202.6 billion, North Chicago, Illinois-based Abbott Laboratories (ABT) is a global healthcare ...

Abbott Laboratories (NYSE:ABT – Get Free Report) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 12,050,000 shares, a ...

The projected fair value for Abbott Laboratories is US$137 based on 2 Stage Free Cash Flow to Equity Abbott Laboratories' US$119 share price indicates it is trading at similar levels as its fair ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $116.41 ...

ABBOTT PRISM was specifically designed to automatically ... is now being used in most major hospitals and reference laboratories and is now available in the transfusion market.

Copyright © 2024 MarketWatch, Inc. All rights reserved.

Analysts see big upside for these undervalued health care stocks.